LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling

LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling

BackgroundThe genesis of SMAC mimetic drugs is founded on the observation that many cancers amplify IAP proteins to facilitate their survival, and therefore removal of these pathways would re-sensitize the cells towards apoptosis. It has become increasingly clear that SMAC mimetics also interface wi...

Full description

Bibliographic Details
Main Authors: Arya Afsahi, Christopher M. Silvestri, Allyson E. Moore, Carly F. Graham, Kaylyn Bacchiochi, Martine St-Jean, Christopher L. Baker, Robert G. Korneluk, Shawn T. Beug, Eric C. LaCasse, Jonathan L. Bramson
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Immunology
Subjects:
SMAC mimetics
engineered T cells
LCL161
multiple myeloma
cancer immunotherapy
adoptive T cell therapies
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1179827/full

Similar Items

Similar Items